Rezolute’s stock up on interim Phase III tumour HI data
Rezolute’s second Phase III trial of ersodetug, this time in tumour hyperinsulinism (HI), is yielding more promising data, prompting the company’s…
Metabolic Disorders
-
-
Lilly’s weight loss pill shows 13% weight loss in adults over 65 years of age
Eli Lilly’s Foundayo (orforglipron) has led to weight loss of 13% in post-hoc analysis of patients aged over 65 from…
-
ECO 2026: targeting organs, not just weight, defines next wave of obesity therapy
The European Congress on Obesity (ECO) 2026 has historically focused primarily on weight reduction. However, this year, a shift in…
-
Fractyl Health’s GLP-1 gene therapy trial given green light
Fractyl Health’s trial to evaluate a glucagon-like peptide-1 (GLP-1) gene therapy has been approved by European authorities. The open-label, first-in-human,…
-
Boehringer’s weight loss jab as good as Wegovy but not Zepbound
Boehringer Ingelheim’s (BI’s) weight loss jab has shown similar efficacy to Wegovy (semaglutide) but a strength inferior to Zebound (tirzepatide).…
-
ACC 2026: Meta-analysis supports CagriSema as superior first-line therapy in obesity
On 28 March, at the American College of Cardiology (ACC) 75th Annual Scientific Session & Expo in New Orleans, Louisiana,…
-
Wave’s stock crashes 50% on Phase I obesity data
Wave Life Sciences’ stock has crashed by nearly 50% after its Phase I obesity trial showed low levels of weight…
-
Lilly’s triple G agonist succeeds in Phase III diabetes trial
Eli Lilly’s investigational first-in-class GIP, glucagon-like peptide 1 receptor (GLP-1R) and glucagon triple hormone receptor agonist has met its primary endpoints in…
-
Roche and Zealand’s Phase II obesity trial divides analyst opinion
Roche and Zealand Pharma’s co-developed amylin analogue, petrelintide, has met its primary endpoint in a Phase II trial, but the…
-
Novo Nordisk-partnered drug shows 19.7% weight loss in Phase II trial
Novo Nordisk and United Laboratories’ jointly developed triple G drug has achieved a 19.7% weight loss in a Phase II…
